ArticleMaterials today. Bio2026
Spatiotemporal liposome-zwitterionic nano-hydrogel orchestrates immunomodulation and neurogenesis in spinal cord injury repair.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following spinal cord injury (SCI), the sequential dysregulation of the inflammatory microenvironment coupled with insufficient endogenous neuroregeneration severely impedes functional recovery. Conventional pharmacotherapies targeting singular pathological cascades and systemic drug administration fail to achieve comprehensive neural repair. Herein, an engineered liposome-zwitterionic nano-hydrogel drug delivery system (RA@Lip/Met-HSB) loaded with the novel neuromodulator retinoic acid (RA) and anti-inflammatory agent metformin (Met) was designed. This system enables temporally programmed release at the lesion site, leveraging the hierarchical degradation of the zwitterionic hydrogel and liposome. Mechanistically, this system orchestrates dual-phase therapeutic actions including acute-phase Met release drives microglial M2 polarization and attenuates neuronal apoptosis, while chronic-phase RA release promotes neural stem cells (NSCs) differentiation into functional neurons and oligodendrocytes, enhancing neuronal signal transmission efficiency via axonal remyelination. In murine SCI models, this system significantly restored motor function through: acute immunomodulation by reducing neuroinflammation and reduces apoptosis, thereby preserving endogenous NSCs, whereas chronic neural remodeling by boosting neurogenesis and facilitating remyelination, axonal regrowth and functional synapse formation. Collectively, this temporally programmed delivery strategy demonstrates robust spatiotemporal immunomodulation and neurogenesis, providing a transformative clinical rationale of the paradigm shift in SCI therapeutics for transitioning drug delivery from systemic to localized, and from temporally unordered to programmed drug administration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.